Human Papillomavirus Type16- L1 VLP Production in Insect Cells

Document Type : Original Article


1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2 Influenza Research Lab, Department of Virology, Pasteur Institute of Iran, Tehran, Iran

3 Department of Anatomy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran


Objective(s):  Infection by high-risk papillomavirus is regarded as the major risk factor in the development of cervical cancer. Recombinant DNA technology allows expression of the L1 major capsid protein of HPV in different expression systems, which has intrinsic capacity to self-assemble into viral-like particles (VLP). VLPS are non-infectious, highly immunogenic and can elicit neutralizing antibodies. VLP-based HPV vaccines can prevent persistent HPV infections and cervical cancer. In this study recombinant HPV-16 L1 protein was produced in Sf9 insect cells and VLP formation was confirmed.
Materials and Methods: Complete HPV-16 L1 gene was inserted into pFast HTa plasmid and transformed into DH10BAC Escherichia coli containing bacmid and helper plasmid. The recombinant Bacmid colonies turned to white and non-recombinant colonies harboring L1 gene remained blue in the presence of X-gal and IPTG in colony selection strategy. To confirm the recombinant bacmid production, PCR was applied using specific L1 primers. To produce recombinant baculovirus, the recombinant bacmid DNA was extracted and transfected into Sf9 cells using Cellfectin. The expression of L1 in Sf9 cells was identified through SDS-PAGE and western blot analysis using specific L1 monoclonal antibody. Self-assembled HPV16L-VLPs in Sf9 cells was confirmed by electron microscopy.
Results:The recombinant protein L1 was predominantly ~60 KD in SDS-PAGE with distinct immunoreactivity in western blot analysis and formed VLPS as confirmed by electron microscopy.
Conclusion:Application of recombinant baculovirus containing HPV-16 L1 gene will certainly prove to be a constructive tool in production of VLPs for prophylactic vaccine development as well as diagnostic tests.


1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. No JH, Kim MK, Jeon YT, Kim YB, Song YS. Human papillomavirus vaccine: widening the scope for cancer prevention. Mol Carcinog 2011; 50:244-253.
3. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a Worldwide Perspective. J Natl Cancer Inst  1995; 87:796-802.
4. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37:4-66.
5. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, Mcknight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors, Gynecol Oncol 2002;84:263-70.
6. Bishop B, Dasgupta J, Klein M, Garcea RL. Christensen ND, Zhao R, et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007; 282:31803-1811.
7. Baker TS, Newcomb WW, Olson NH, Cowsert LM,  Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991; 60:1445-1456.
8. Finnen RL, Erickson KD, Chen XS, Garcea RL. Interactions between Papillomavirus L1 and L2 Capsid Proteins. J Virol 2003; 77:4818-4826.
9. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67:6929-6936.
10. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
11. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized, controlled trial. Lancet 2004; 364:1757-1765.
12. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer  2006; 95:1459-1466.
13. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med  2007; 356:1908-1910.
14. Teimoori A, Soleimanjahi H, Fotouhi F, Meshkat Z. Isolation and cloning of human papillomavirus 16 L1 gene from Iranian isolate. Saudi Med J 2008; 29:1105-1108.
15. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3th ed. New York: Cold Spring; 2001.
16. Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. FEMS Immunol Med Microbiol  2008; 54:18-26.
17. Liao S, Wang S, Xu L, Deng D, Xu Q, Wang W, et al. Production and verification of human papillomavirus type 18 vaccine in vitro. Oncol Rep 2008; 20:211-217.
18. Soleimanjahi H, Roostaee MH, Rasaee MJ, Mahboudi F, Kazemnejad A, Bamdad T, et al. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections. FEMS Immunol Med Microbiol  2006 ; 46:100-106.
19. Bozzola JJ, D L. Electron Microscopy, principal and techniques for biologies. USA: Jones &Bartlett; 1998.
20. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4:46-54.
21. Ghaebi Nayereh K, Meshkat Z. Vaccines against human Papipillomaviruses associated cervical cancers. Iran J Basic Med Sci  2012; 15:585-601.
22. Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005; 23:567-575.
23. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89:12180-1214.
24. Touze A, El Mehdaoui S, Sizaret PY, Mougin C, Munoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 1998; 36:2046-2051.
25. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 LI and L1-L2 into virus-like particles. J Virol  1993; 67:6929.